Anti-mens VEGF (Bevacizumab) Fc MutedBiotine

Expression Host : HEK-293 This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab. Bevacizumab recognizes both native and reduced human VEGF (isoform 165) . This product is for research use only. Bevacizumab is a monoclonal antibody that specifically recognizes vascular endothelial growth factor (VEGF) . VEGF is a growth factor that participates in angiogenesis, vasculogenesis, and endothelial cell growth. It facilitates endothelial cell proliferation, cell migration, and the permeabilization of blood vessels. In addition, VEGF inhibits apoptosis. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the regression of tumor vascularization, normalization of remaining tumor vasculature, and inhibition of the formation of new tumor vasculature, thus inhibiting tumor growth.1 Anti-Human VEGF (Bevacizumab) utilizes the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research projects.

Vascular Endothelial Growth Factor; VEGF-A; VEGFA; Vascular Permeability Factor; VPF

Human

Recombinant human VEGF.

VEGF

A4.6.1

ELISA

Concentration : 0.5 mg/mlThis Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.

The suggested concentration for Adalimumab biosimilar antibody for staining cells in flow cytometry is <= 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.ELISA

Human IgG1k